Outcomes After Diagnosis of Mycosis Fungoides and Sézary Syndrome Before 30 Years of Age
Weiyun Z. Ai(City College of San Francisco), Ellen T. Chang(Exponent (United States)), David J. Press(Cancer Prevention Institute of California), Theresa H.M. Keegan(UC Davis Comprehensive Cancer Center), Youn H. Kim(Stanford University), Laura B. Pincus(University of California, San Francisco), Juan Yang(University of California, San Francisco)
Cited by 35
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487